Author

Joaquin Hinojosa

ACTIVATION OF WNT SIGNALLING BY M2A MACROPHAGES PROMOTES MUCOSAL REPAIR IN MURINE IBD

Jesus Cosin-Roger, Dolores Ortiz-Masia, Dulce Carolina Macías-Ceja, Sara Calatayud, Carlos Hernandez, Joaquin Hinojosa, Maria Dolores Barrachina

CLINICAL DIFFERENTIAL CHARACTERISTICS OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) OF ONSET IN PEDIATRIC AGE COMPARED TO PATIENTS DIAGNOSED IN ADULTHOOD

Maria Chaparro Sanchez, Ana Garre, Elena Ricart, Valle García-Sánchez, Carlos Taxonera, Miriam Mañosa, Isabel Vera Mendoza, Miguel Mínguez, Federico Argüelles, Luisa de Castro, M Arroyo, Antonio López-Sanromán, Montserrat Rivero Tirado, Jordi Guardiola Capon, María Dolores Martín-Arranz, Belen Beltran, Jesús Barrio, Sabino

Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry

Margalida Calafat Sard, Miriam Mañosa, Elena Ricart, Pilar Nos Mateu, Eva Iglesias, Isabel Vera, Antonio López-San Román, Jordi Guardiola, Carlos Taxonera, Miguel Mínguez, Mariló Martin-Arranz, Luisa de Castro, Sabino Riestra, Montserrat Rivero, Esther García-Planella, Xavier Calvet, Santiago García-López, Montserrat Andre

APPRECIA: ADALIMUMAB VS AZATHIOPRINE IN THE PREVENTION OF CROHN’S DISEASE RECURRENCE AFTER SURGICAL RESECTION. A GETECCU MULTICENTER RANDOMIZED TRIAL.

Antonio López San Román, Isabel Vera Mendoza, Eugeni Domenech Morral, Carlos Taxonera, Vicente Vega, Ignacio Marín-Jiménez, Jordi Guardiola Capon, Luisa Castro, Maria Esteve Comas, Valle García, Daniel Ceballos, Pilar Martínez-Montiel, Javier Gisbert, Miguel Mínguez, Ana Echarri Piudo, Xavier Calvet Calvo, Jesús Barrio, Jo

Delphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care Units

Xavier Calvet Calvo, Noelia Alfaro, Joaquin Hinojosa, Beatriz Sicilia, Marta Gallego, Ildefonso Pérez, Pablo Lázaro y de Mercado, Fernando Gomollon Garcia

EFFICACY AND SAFETY OF THE SEQUENTIAL USE OF A SECOND AND THIRD ANTI-TNF DRUG IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Maria José Casanova, Maria Chaparro Sanchez, Miguel Mínguez, Elena Ricart, Carlos Taxonera, Santiago García-López, Jordi Guardiola Capon, Antonio López-San Román, Eva Iglesias, Pilar Nos, Beatriz Sicilia, Maria Isabel Vera, Joaquin Hinojosa, Sabino Riestra, Eugeni Domenech Morral, Xavier Calvet Calvo, José Lázaro Pérez-Call

Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease

Maria Chaparro Sanchez, A Aterido, Ivan Guerra, Marisa Iborra, Jose Luis Cabriada, Luis Bujanda, Carlos Taxonera, Eva Iglesias-Flores, Ignacio Marín-Jiménez, Manu Barreiro de-Acosta, Isabel Vera, Maria Dolores Martín Arranz, Borja Hernández-Breijo, Fernando Mesonero, Laura Sempere, Fernando Gomollón, Joaquin Hinojosa, Alic

The GETECCU clinical guideline for the treatment of ulcerative colitis: A guideline created using GRADE methodology

Fernando Gomollon Garcia, Santiago García-López, Beatriz Sicilia, Joaquin Hinojosa

USE OF ANTI-TNF AGENTS FOR PRIMARY PREVENTION OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE: A NATIONWIDE, REAL-LIFE STUDY. RESULTS FROM THE SPANISH ENEIDA REGISTRY

Eugeni Domenech Morral, Fiorella Cañete, Miriam Mañosa, Maria José Casanova, Ramiro C González Sueyro, Jesús Barrio, Fernando Bermejo, Pilar Nos, Eva Iglesias Flores, Esther García Planella, José Lázaro Pérez Calle, Raquel Vicente Lidón, Montserrat Rivero, Laura Ramos, Maribel Vera, Ruth De Francisco, Antonia Montserrat Tor

Item 1 - 9 / 9
1
We use cookies in order to provide you with a better browsing experience. This includes third-party cookies for traffic analyzation purposes. See here for more information.
OK